New year, new job?
We have two vacancies for talented and enthusiastic professionals.
The Legal Regulatory Policy Analyst
will provide sound legal and regulatory analysis for PHG Foundation’s health policy projects. The successful candidate will have a good first degree in law, social science, philosophy or similar subject; an excellent grasp of the legal, regulatory and ethical landscape around genomics and healthcare; first class analytical, drafting and communication skills and the ability to transfer their academic grounding into actionable policy applications.
The Business Development Manager
will develop and manage the commercial offer of the PHG Foundation. Working with the Senior Management Team they will develop and sell products and services to generate significant new income to support the Foundation’s long term sustainability. The successful candidate will ideally have a good track record of marketing and income generation in the healthcare sector for example in industries such as diagnostics, pharmaceutical, biotechnology and healthcare management consultancy.
PHG Foundation launches a new project this month investigating ctDNA technologies - specifically the so-called ‘liquid biopsy’ - the cancers in which they could have an impact and the issues arising from implementation of ctDNA testing within the health system. Continuing our series of bite-size overviews of emerging technologies, Laura Blackburn outlines the challenges ahead for proteome analysis and how this complex field of research could form an important part of the personalised medicine toolkit. In the news, interim data from trials run by US-based Voyager Therapeutics Inc. suggest that a combination of gene therapy and the drug, levodopa, can improve the Unified Parkinson's disease rating scale of a patient by up to 55%. Circulating tumour DNA technology: the future of cancer management?
Clinical proteome analysis – the key to personalised healthcare
Combined gene-therapy and pharmaceutical treatment for Parkinson's disease
Science and health policy
The world’s largest publicly available ‘genome bank’ of specifically healthy older people has been launched by the Garvan Institute of Medical Research. It is anticipated the data bank will help overcome a challenge of genomic research - working out which genetic variants act as drivers of disease, and which do not. Scientists at the McEwen Centre for Regenerative Medicine, Toronto, have used stem cells to create a lifelong cure for those who need a pacemaker, in the form of new ‘pacemaker’ heart cells. Finally, if you would like a flavour of the discussions at our recent sell out conference Personalised Healthcare: making the most of genomics, take a look at our storify. News of events from the Life Sciences & Society series for 2017 will be available early in the new year.Genomes of healthy older Australians to accelerate genomic discovery
Building a biological pacemaker out of stem cells
Personalised healthcare: making the most of genomics